CureVac AG
CureVac uses mRNA as an information carrier, which enables the body to produce its own active ingredients for the fight against various diseases.
CureVac is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing, optimizing and manufacturing this versatile biological molecule for medical purposes. The principle of CureVac’s proprietary technology is the use of optimized mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases. In July 2020, CureVac entered into a collaboration with GSK to jointly develop new products in prophylactic vaccines for infectious diseases based on CureVac’s second-generation mRNA technology. This collaboration was later extended to the development of second-generation COVID-19 vaccine candidates and modified mRNA vaccine technologies. Based on its proprietary technology, CureVac has built a deep clinical pipeline across the areas of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases. CureVac had its initial public offering on the New York Nasdaq in August 2020. It is headquartered in Tübingen, Germany, and employs more than 900 people across its sites in Tübingen, Frankfurt, and Boston, USA. Further information can be found at www.curevac.com.
Category | Biotechnology |
---|---|
Working areas | Biotechnology, Research, Medical products, Production |
Year of foundation | |
Employees |
Contact
Friedrich-Miescher-Straße 15
72076 Tübingen
+49 7071 9883 - 0
communications@curevac.com
https://www.curevac.com/
News
CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK
TÜBINGEN, Germany / BOSTON, USA – April 4, 2024 CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines…
CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE
TÜBINGEN, Germany / BOSTON, USA – December 19, 2023 CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines…
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update
CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today…
CureVac Reports Progress in Intellectual Property Infringement Case Against BioNTech in Germany
Regional Court Düsseldorf postpones infringement ruling on four intellectual property rights in lawsuit filed by CureVac against BioNTech Ruling on infringement to be provided…